Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Evofem Biosciences Inc
EVFM
Healthcare
Biotechnology
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled...
applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:EVFM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Jan 08, 2024 8:31am
New Press Release - Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
— Removal of Prior Authorization Upgrades Phexxi Coverage for Nearly 1.8 Million Washington Lives Across All Medicaid Plans—— Fans Encouraged to Plan for Victory, Prevent Unintended Pregnancy —SAN DIEGO, Jan. 8, 2024 /PRNewswire/ -- Multiple studies have shown that testosterone levels surge in...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 19, 2023 11:38am
New Press Release - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI
NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:Codorus Valley Bancorp, Inc. (NASDAQ: CVLY)'s...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 18, 2023 2:30pm
New Press Release - EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosciences, Inc. (OTC: EVFM) to Aditxt, Inc. (NasdaqCM: ADTX) in consideration of the issuance of a combination of common stock and...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 13, 2023 7:39pm
New Press Release - Lifshitz Law PLLC Announces Investigations of IMGN, HA, CERE, and EVFM
NEW YORK, NY / ACCESSWIRE / December 13, 2023 / Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IMGN to AbbVie, Inc. for $31.26 in cash per share of IMGN owned.ImmunoGen, Inc. (NASDAQ:IMGN)Lifshitz Law PLLC announces an...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 13, 2023 12:49pm
New Press Release - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, CVLY, EVFM, EAR
NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:CapStar Financial Holdings, Inc. (NASDAQ: CSTR)'s...
read article.
(475)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 13, 2023 11:06am
EVFM....The only winner here was the optimist who
bought this 2 days ago and sold yesterday Next !
(475)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 12, 2023 3:36pm
EVFM....FWIW 150K sh block just traded
Interesting
(475)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 12, 2023 12:36pm
EVFM....still watching....should move up IMHO
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi ‚ ®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse
...more
(475)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 12, 2023 10:32am
EVFM..... A break of ~ $0.25 would be very positive ; )
Just watching....no position
(475)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 12, 2023 10:24am
EVFM.....taken over by ADTX...EVFM trades OTC
Who knows where this will go to On watch
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 10, 2022 8:24pm
New Press Release - Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
-- Conference Call Scheduled for 5:00 p.m. ET --SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:Date:Thursday, August 11, 2022 Time:5:00 p.m. ET (2:00 p.m. PT) Live call:(877) 445-9755 (U.S. toll-free) or (201) 493-6744...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 09, 2022 8:02am
New Press Release - Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 04, 2022 4:02pm
New Press Release - Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance
-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter ---- Reduced operating expense by 8% and improved loss from operations by 16% ---- Completed registrational Phase 3 trial evaluating Phexxi for the prevention of chlamydia and...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 03, 2022 8:24am
New Press Release - Evofem Biosciences Strengthens Board of Directors
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 01, 2022 9:01am
New Press Release - Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate...
read article.
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.